Sol-Gel Technologies Announces Seventh Agreement


Sol-Gel Technologies, Ltd. recently announced it has entered into a seventh collaborative agreement with Perrigo Israel, an affiliate of Perrigo Company plc for the development, manufacturing, and commercialization of two new generic formulations of antibiotic foams.

Consistent with Sol-Gel’s prior agreements with Perrigo, Perrigo will seek regulatory approval with the US FDA for these generic product candidates. If approved by the FDA, Perrigo has agreed to commercialize the generic product candidates in the US. Sol-Gel and Perrigo will share the development costs and the gross profits generated from sales of the generic product candidates, if approved.

“Sol-Gel is pleased at the opportunity to continue to build its successful, revenue-generating portfolio of complex generics with first-to-file potential with its partner, Perrigo, as well as help further their vision of affordable prescription generics,” said Dr. Alon Seri-Levy, Chief Executive Officer of Sol-Gel. “With top-line revenue being generated from our generics portfolio, we look forward to continuing the development of our innovative, branded products, which are currently in Phase 3 pivotal trials with top-line data expected in mid-2019 for Epsolay and TWIN in the fourth quarter of this year.”

Sol-Gel is a clinical-stage dermatology company focused on identifying, developing, and commercializing branded and generic topical drug products for the treatment of skin diseases. Sol-Gel’s current product candidate pipeline consists of late-stage branded product candidates that leverage our proprietary, silica-based microencapsulation technology platform, and several generic product candidates across multiple indications. For more information, visit www.sol-gel.com.

Share This